BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
World's top technology exhibition CES 2021
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Chong Kun Dang's anemia biosimilar wins regulatory approval at home

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : December 3, 2018, 10:13 | Updated : December 3, 2018, 10:13
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Chong Kun Dang]



SEOUL -- CKD-11101, a biosimilar developed by South Korea's pharmaceutical company Chong Kun Dang has won regulatory approval at home to sell the world's first copycat of Nesp for the treatment of anemia of chronic disease associated with cancer.

Chong Kun Dang said the Ministry of Food and Drug Safety has approved CKD-11101. Marketing is possible in South Korea next year. It is the world's first biosimilar referencing Nesp codeveloped by Japan’s Kyowa Hakko Kirin and Amgen.

Through a partnership with a multinational company, Chong Kun Dang's biosimilar has filed for approval in Japan. The company has patented CKD-11101 in Europe and the United States to accelerate global sales.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Celltrion teams up with British bio company to develop oral infliximab.
    Celltrion teams up with British bio company to develop oral …
  • .Alteogen secures new technology export deal with ALT-B4 human hyaluronidase technology.
    Alteogen secures new technology export deal with ALT-B4 huma…
  • .Samsung BioLogics makes $1.47 bln investment to build fourth plant.
    Samsung BioLogics makes $1.47 bln investment to build fourth…
  • .Celltrion aims to become global pharmaceutical company through deal with Takeda.
    Celltrion aims to become global pharmaceutical company throu…
  • .Remsima SC wins approval for additional indications in Europe.
    Remsima SC wins approval for additional indications in Europ…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • Singer IU drops teaser image for upcoming full album
  • Hyundai to complete construction of fuel cell production plant in China in 2022
  • Seoul builds solar power plant on idle land near urban expressway
  • Samsung showcases new Galaxy S21 smartphone models
  • Southern city launches joint research project to develop heavy-duty flying taxi drone
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view